semaglutide trevogrumab garetosmab GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates The investigational monoclonal antibody trevogrumab

Primary constipation is caused by anorectal and colonic problems, while secondary constipation is caused by organic and metabolic diseases or medications

Manufactured by Eli Lilly and Company and first approved in September 2014, Trulicity holds two distinct FDA indications: glycemic control in adults with type 2 diabetes, and cardiovascular risk reduction making it the first and only type 2 diabetes medicine approved to reduce the risk of major cardiovascular events in both patients with established heart disease and those with multiple cardiovascular risk factors but no prior cardiac event (primary and secondary prevention)

Dobretsov M, Romanovsky D, Stimers JR

PMID: 3525654 Messerli FH, Eslava DJ (2008): Treatment of hypertensive emergencies: blood pressure cosmetics or outcome evidence